Pre-made Loncastuximab Tesirine benchmark antibody (Whole mAb ADC, anti-CD19 therapeutic antibody, Anti-B4/CVID3 Antibody) for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-INN-896

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

SKU GMP-Bios-INN-896 Category Tag

Product Details

Pre-made Loncastuximab Tesirine benchmark antibody (Whole mAb ADC, anti-CD19 therapeutic antibody, Anti-B4/CVID3 Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Loncastuximab tesirine , sold under the brand name Zynlonta, is a monoclonal antibody conjugate medication used to treat large B-cell lymphoma.[1] It is an antibody-drug conjugate (ADC) composed of a humanized antibody targeting the protein CD19.[1]

Products Name (INN Index)

Pre-Made Loncastuximab Tesirine Biosimilar, Whole Mab Adc, Anti-Cd19 Antibody: Anti-B4/CVID3 therapeutic antibody Drug Conjugate

INN Name

loncastuximab tesirine

Target

CD19

Format

Whole mAb ADC

Derivation

Chimeric

Species Reactivity

Human

CH1 Isotype

IgG1 – kappa

VD LC

IgG1 – kappa

Highest_Clin_Trial (Jan '20)

NA

Est. Status

NA

100% SI Structure

NA

99% SI Structure

NA

95-98% SI Structure

NA

Year Proposed

NA

Companies

ADC?Therapeutics (Epalinges Switzerland)

Conditions Approved

NA

Conditions Active

NA

Conditions Discontinued

NA

Development Tech

NA

Previous Name

NA

Gm Offical Target Name

CD19

Package

, ,

Genemeidi Omicron Variant Products
test
Previous slide
Next slide